ArticleInfectious diseases and therapy2026
Post-Marketing Active Surveillance of Adverse Events Following Quadrivalent Subunit Influenza Vaccine in Healthy Participants Aged ≥ 3 Years in China.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionThe observational phase IV study through an active surveillance system aimed to assess the safety of the subunit influenza vaccine in healthy individuals aged ≥ 3 years and explore the feasibility of using an active adverse event (AE) surveillance system based on a WeChat Mini Program incorporating electronic diary cards (e-diary cards) in China.
methodsBetween October 30, 2023, and April 28, 2025, a multi-center, open-label, single-arm prospective active surveillance study was conducted. Healthy individuals aged 3 years and above who voluntarily and at their own expense came to the outpatient department to receive the target vaccine (Ab&B Biotech Co., Ltd., Jiangsu, China) were recruited as research participants. The WeChat Mini Program was employed to record baseline information and the occurrence of AEs and adverse drug reactions (ADRs) within 28 days after vaccination. A post hoc subgroup analysis was conducted to assess the safety characteristics of participants in different age groups.
resultsAmong the 42,881 participants, 495 (11.54‰) reported a total of 682 AEs. No vaccine-related serious adverse events (SAEs) were reported. A total of 293 participants (6.83‰) reported 374 ADRs. Among these, 29 participants (0.68‰) reported 34 unsolicited ADRs, including pharyngalgia (n = 10, 0.23‰) and rhinorrhea (n = 4, 0.09‰) among others. The incidence rates (IR) of AEs across 3-8, 9-17, 18-64, ≥ 65 years groups, from youngest to oldest, were 16.29‰ (n = 269), 10.63‰ (n = 58), 10.53‰ (n = 145), and 3.21‰ (n = 23). A statistically significant difference in AE incidence was observed among the age groups (P < 0.001).
conclusionsThe vaccine demonstrated a favorable safety profile in healthy individuals aged 3 years and above. Moreover, the active surveillance method with the Mini Program was helpful in detecting very rare ADRs.
trial registrationNCT073326896. Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.